Baff and rheumatic autoimmune disorders: Implications for disease management and therapy

International Journal of Immunopathology and Pharmacology

Volumn 20, Issue 1, 2007, Pages 1-8

  Bosello, S ^a,b   Pers, J O ^a   Rochas, C ^a   Devauchelle, V ^a   De Santis, M ^a   Daridon, C ^a   Saraux, A ^a   Ferraccioli, G F ^a   Youinou, P ^a,c  

^a Medical School   (France)

^b CATHOLIC UNIVERSITY   (Italy)

^c BREST UNIVERSITY HOSPITAL   (France)

Author keywords

Autoimmunity; B cell activating factor; B lymphocyte; Rheumatoid arthritis; Sj gren's syndrome; Systemic lupus erythematosus

Indexed keywords

AUTOANTIBODY; HYBRID PROTEIN; MEMBRANE PROTEIN; PROTEIN BAFF; PROTEIN INHIBITOR; TUMOR NECROSIS FACTOR; UNCLASSIFIED DRUG;

ANTIBODY PRODUCING CELL; AUTOIMMUNE DISEASE; B LYMPHOCYTE; CELL DIFFERENTIATION; CHRONIC LYMPHATIC LEUKEMIA; CLINICAL FEATURE; CYTOKINE PRODUCTION; HUMAN; HYPERGAMMAGLOBULINEMIA; IMMUNOGLOBULIN BLOOD LEVEL; IMMUNOLOGICAL TOLERANCE; NONHUMAN; PRIORITY JOURNAL; PROTEIN EXPRESSION; REVIEW; RHEUMATIC DISEASE; RHEUMATOID ARTHRITIS; SJOEGREN SYNDROME; SYSTEMIC LUPUS ERYTHEMATOSUS; SYSTEMIC SCLEROSIS;

EID: 33947729198     PISSN: 03946320     EISSN: None     Source Type: Journal    
DOI: 10.1177/039463200702000101     Document Type: Review

References (36)

1. Youinou P., C. Jamin, J.O. Pers, C. Berthou, A. Saraux and Y. Renaudineau. 2005. B lymphocytes are required for development and treatment of autoimmune diseases. Ann. N.Y. Acad. Sci. 1050:19.
2. Edwards J.C.W. and G. Cambridge. 2006. B-cell targeting in rheumatoid arthritis and other autoimmune diseases. Nat. Rev. Immunol. 6:394.
3. Mackay F. and J.L. Browning. 2002. BAFF: a fundamental survival factor for B cells. Nat. Rev. Immunol. 2:465.
4. Kalled S.L., C. Ambrose and Y.M. Hsu. 2005. The biochemistry and biology of BAFF, APRIL and their receptors. Curr. Dis. Autoimmun. 8:206.
5. Daridon C., P. Youinou and J.O. Pers. 2006. BAFF, APRIL, TWE-PRIL: who's who? Autoimmun. Rev. in press.
6. Youinou P., C. Jamin and P.M. Lydyard. 1999. CD5 expression in human B-cell population. Immunol. Today 20:312.
7. Ng L.G., A.P. Sutherland, R. Newton, F. Qian, T.G. Cachero, M.L. Scott, J.S. Thompson, J. Wheway, T. Chtanova, J. Groom, I.J. Sutton, C. Xin, S.G. Tangye, S.L. Kalled, F. Mackay and C.R. Mackay. 2004. B cell-activating factor belonging to the TNF family (BAFF)-R is the principal BAFF receptor facilitating BAFF costimulation of circulating T and B cells. J. Immunol. 173:807.
8. Roschke V., S. Sosnovtseva, C.D. Ward, J.S. Hong, R. Smith, V. Albert, W. Stohl, K.P. Baker, S. Ullrich, B. Nardelli, D.M. Hilbert and T.S. Migone. 2002. BLyS and APRIL form biologically active heterotrimers that are expressed in patients with systemic immune-based rheumatic disease. J. Immunol. 169:4314.
9. Batten M., J. Groom, T.G. Cachero, F. Qian, P. Schneider, J. Tschopp, J.L. Browning and F. Mackay. 2000. BAFF mediates survival of peripheral immature B lymphocytes. J. Exp. Med. 192:1453.
10. Tardivel A., A. Tinel, S. Lens, Q.G. Steiner, E. Sauberli, A. Wilson, F. Mackay, A.G. Rolink, F. Beermann, J. Tschopp and P. Schneider. 2004. The anti-apoptotic factor Bcl-2 can functionally substitute for the B cell survival but not for the marginal zone B cell differentiation activity of BAFF. Eur. J. Immunol. 34:509.
11. Hsu B.L., S.M. Harless, R.C. Lindsley, D.M. Hilbert and M.P. Cancro. 2000. Cutting edge: BLyS enables survival of transitional and mature B cells through distinct mediators. J. Immunol. 168:5993.
12. Huard B., P. Schneider, D. Mauri, J. Tschopp and L.E. French. 2001. T cell costimulation by the TNF ligand BAFF. J. Immunol. 167:6225.
13. Mackay F., S.A. Woodcock, P. Lawton, C. Ambrose, M. Baetscher, P. Schneider, J. Tschopp and J.L. Browning. 1999. Mice transgenic for BAFF develop lymphocytic disorders along with autoimmune manifestations. J. Exp. Med. 190:1697.
14. Groom J., S.J. Kalled, A.H. Cutler, C. Olson, S.A. Woodcock, P. Schneider, J. Tschopp, T.G. Cachero, M. Batten, J. Wheway, D. Mauri, D. Cavill, T.P. Gordon, C.R. Mackay and F. Mackay. 2002. Association of BAFF/BLyS overexpression and altered B cell differentiation with Sjogren's syndrome. J. Clin. Invest. 109:59.
15. Xia X.Z., J. Treanor, G. Senaldi et al. 2000. TACI is a TRAF-interacting receptor for TALL-1, a tumor necrosis factor family member involved in B cell regulation. J. Exp. Med. 192:137.
16. Thompson J.S., P. Schneider, S.L. Kalled et al. 2000. BAFF binds to the tumor necrosis factor receptor-like molecule B cell maturation antigen and is important for maintaining the peripheral B cell population. J. Exp. Med. 192:129.
17. Thien M., T.G. Phan, S. Gardam, M. Amesbury, A. Basten, F. Mackay and R. Brink. 2004. Excess BAFF rescues self-reactive B cells from peripheral deletion and allows them to enter forbidden follicular and marginal zone niches. Immunity 20:785.
18. Pers J.O., C. Daridon, V. Devauchelle, S. Jousse, A. Saraux, C. Jamin and P. Youinou. 2005. BAFF overexpression is associated with autoantibody production in autoimmune disease. Ann. N.Y. Acad. Sci. 1050:34.
19. Chan O.T., L.G. Hannum, A.M. Haberman, M.P. Madaio and M.J. Shlomchik. 1999. A novel mouse with B cells but lacking serum antibody reveals an antibody-independent role for B cells in murine lupus. J. Exp. Med. 189:1639.
20. Zhang J., V. Roschke, K.P. Baker, Z. Wang, G.S. Alarcon, B.J. Fessler, H. Bastian, R.P. Kimberly and T. Zhou. 2001. A role for B lymphocyte stimulator in systemic lupus erythematosus. J. Immunol. 166:6.
21. Stohl W., S. Metyas, S.M. Tan, G.S. Cheema, B. Oamar, D. Xu, V. Roschke, Y. Wu, K.P. Baker and D.M. Hilbert. 2003. B lymphocyte stimulator overexpression in patients with systemic lupus erythematosus: longitudinal observations. Arthritis Rheum. 48:3475.
22. Ramanujam M., X. Wang, W. Huang, Z. Liu, L. Schiffer, H. Tao, D. Frank, J. Rice, B. Diamond, K.O. Yu, S. Porcelli and A. Davidson. 2006. Similarities and differences between selective and nonselective BAFF blockade in murine SLE. J. Clin. Invest. 116:724.
23. Baker K.P., B.M. Edwards, S.H. Main et al. 2003. Generation and characterisation Lymphostat-B, a human monoclonal antibody that antagonised the bioactivities of B lymphocyte stimulator. Arthritis Rheum. 48:3253.
24. Svensson L., J. Jirholt, R. Holmdahl and L. Jansson. 1998. B cell-deficient mice do not develop type II collagen-induced arthritis (CIA). Clin. Exp. Immunol. 111:521.
25. Cambridge G., W. Stohl, M.J. Leandro, T.S. Migone, D.M. Hilbert and J.C. Edwards. 2006. Circulating levels of B lymphocyte stimulator in patients with rheumatoid arthritis following Rituximab treatment: relationships with B cell depletion, circulating antibodies and clinical relapse. Arthritis Rheum. 54:723.
26. Wang H., S.A. Marsters, T. Baker, B. Chan, W.P. Lee, L. Fu, D. Tumas, M. Yan, V.M. Dixit, A. Ashkenazi and I.S. Grewal. 2001. TACI-ligand interactions are required for T cells activation and collagen-induced arthritis in mice. Nat. Immunol. 2:632.
27. Seyler T.M., Y.W. Park, S. Takemura, R.J. Bram, P.J. Rurtin, J.J. Goronzy and C. Weyand. 2005. BLyS and APRIL in rheumatoid arthritis. J. Clin. Invest. 115:3083.
28. Quartuccio L., M. Fabris and G. Ferraccioli. 2004. B lymphocyte stimulator (BLyS) and monocytes: possible role in autoimmune diseases with a particular reference to rheumatoid arthritis. Reumatismo 56:143.
29. Tan S.M., D. Xu, V. Roschke, J.W. Perry, D.G. Arkfeld, G.R. Ehresmann, T.S. Migone, D.M. Hilbert and W. Stohl. 2003. Local production of B lymphocyte stimulator protein and APRIL in arthritic joints of patients with inflammatory arthritis. Arthritis Rheum. 48:982.
30. Gross J.A., S.R. Dillon, S. Mudri et al. 2001. TACI-Ig neutralises molecules critical for B cell development and autoimmune disease: impaired B cell maturation in mice lacking BLyS. Immunity 15:289.
31. Jonsson M.V., P. Szodoray, S. Jellestad, R. Jonsson and K. Skarstein. 2005. Association between circulating levels of the novel TNF family member APRIL and BAFF and lymphoid organization in primary Sjögren's syndrome. J. Clin. Immunol. 25:189.
32. Mackay F., F. Sierro, S.T. Grey and T.P. Gordon. 2005. The BAFF/APRIL system: an important player in systemic rheumatic diseases. Curr. Dir. Autoimmun. 8:234.
33. Szodoray P., S. Jellestad, M.O. Teague and R. Jonsson. 2003. Attenuated apoptosis of B cell activating factor-expressing cells in primary Sjögren's syndrome. Lab. Invest. 83:357.
34. Gasparotto D., S. De Vita, V. De Re, A. Marzotto, G. De Marchi, C.A. Scott, A. Gloghini, G. Ferraccioli and M. Boiocchi. 2003. Extrasalivary lymphoma development in Sjögren's syndrome: clonal evolution from parotid gland lymphoproliferation and role of local triggering. Arthritis Rheum. 48:3181.
35. Saito E., M. Fujimoto, M. Hasegawa, K. Komura, Y. Hamaguchi, Y. Kaburagi, T. Nagaoka, K. Takehara, T.F. Tedder and S. Sato. 2002. CD 19-dependent B lymphocyte signaling threshold influenced skin fibrosis and autoimmunity in the tight-skin mouse. J. Clin. Invest. 109:1453.
36. Matsushita T., M. Hasegawa, K. Yanaba, M. Kodera, K. Takehara and S. Sato. 2006. Elevated serum BAFF levels in patients with systemic sclerosis: enhanced BAFF signaling in systemic sclerosis B lymphocytes. Arthritis Rheum. 54:192.